PTC Therapeutics
PTCTPTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.In September 2009, PTC entered into an agreement with R …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at PTC Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 5/16/2025 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $46.0 | $40,636 |
| 5/15/2025 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $46.2 | $89,081 |
| 4/22/2025 | Sell | Klein, Matthew B. | CHIEF EXECUTIVE OFFICER | $48.7 | $136,656 |
| 4/2/2025 | Sell | Golden, Lee Scott | EVP & CHIEF MEDICAL OFFICER | $47.0 | $42,114 |
| 3/17/2025 | Sell | Pauwels, Eric | CHIEF BUSINESS OFFICER | $57.0 | $384,068 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)